ClinicalTrials.gg
CompletedNCT07132957Updated Aug 20, 2025

A Study of AL8326 in Healthy Subjects

A Phase 1 interventional study of 14C-labeled AL8326 in Small Cell Lung Cancer and Solid Tumors, sponsored by Advenchen Laboratories Nanjing Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by Advenchen Laboratories Nanjing Ltd. · Phase 1, Interventional, and Screening

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Enrollment
329th of 333
6 · median 63
Started
2025
with 59 others
Phase 1
43 of 365
24 open now
Registered
269th of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 329th largest by enrollment of the 333 interventional ones that give a count, is one of 60 that started in 2025, is one of 43 in phase 1, and was the 269th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

This experiment plans to enroll 6-8 healthy male subjects in China, and ultimately collect complete test samples and data from at least 6 subjects as the standard. On the first day of the experiment, each subject orally took a single dose of [14C] AL8326 oral formulation containing approximately 60mg (200 μ Ci). During the experiment, whole blood, plasma, urine, and fecal samples were collected at designated time points/time periods.

Read the detailed description

This experiment adopts a single center, open label, non randomized, single dose trial design. By measuring the total radioactivity, calculate the ratio of total radioactivity in whole blood to plasma of [14C] AL8326, pharmacokinetic parameters, recovery rate, and excretion pathway data of total radioactivity in plasma. At the same time, by identifying the spectra of radioactive metabolites and the structures of major metabolites in plasma, urine, and feces, the main metabolic elimination pathways and characteristics of AL8326 in the human body were obtained, as well as the circulating metabolites that are close to or higher than 10% of the total radioactive exposure in plasma.

03

Conditions studied

  • Small Cell Lung Cancer
  • Solid Tumors
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following inclusion criteria to be eligible for this study:

  1. Chinese healthy male subjects, 18 to 45 years of age (inclusive)
  2. (BMI) of 19-26 kg/m2 (inclusive), and body weight not less than 50 kg (inclusive)
  3. Subjects who had no fertility or sperm donation plan from signing the until 1 year after the end of the trial, or those who agreed that the subjects and their partners should strictly use from signing the informed consent until 1 year after the end of the trial; Voluntarily signing the ICF,Ability to communicate well with the investigator and compliance to complete the trial according to the protocol.

Exclusion criteria

Exclusion Criteria:

Subjects presenting with any of the following will not be included in the study:

  1. abnormality of physical examination, vital signs, routine laboratory tests (hematology, blood chemistry, coagulation, urinalysis, and stool routine + occult blood), 12-lead , chest X-ray (anterograde), digital anal examination, thyroid function,ophthalmic examination and abdomen ultrasound (liver, gallbladder, pancreas, spleen, and kidneys), etc.
  2. Subjects with an allergic constitution, such as known allergic history to two or more substances, or allergic diseases, or those who may be hypersensitive to the drug or its , as judged by the investigator;
  3. Gastrointestinal diseases causing clinically significant symptoms such as nausea, vomiting, diarrhea, or malabsorption syndrome; Or a history of severe vomiting or diarrhea within one week before the screening period;
  4. History of dysphagia or any condition that may affect drug absorption (e.g., gastrectomy, cholecystectomy, gastric bypass, duodenotomy, colectomy);
  5. History of any clinical critical illness or presence of diseases or conditions that the investigator considers may affect the trial results, including but not limited to diseases of digestive system, circulatory system, respiratory system, endocrine system, nervous system, urinary system or blood, immune system, psychiatric system and metabolism and nutrition diseases ;
  6. History of organic heart disease, heart failure, myocardial infarction, angina pectoris, torssion ventricular tachycardia, ventricular tachycardia, long syndrome or family history (genetic proof or sudden death of a close relative at a young age);
  7. Major surgery within 6 months before screening or incomplete healing of surgical incision, the major surgeries including but not limited to any procedures that have significant risk of hemorrhage, prolonged general anesthesia, open , or marked traumatic invasive injury;
  8. History of active bleeding (e.g., peptic ulcer, intracranial hemorrhage, skin ecchymosis, gingival bleeding); History of any disease within the previous 6 months that may increase the risk of bleeding (such as tumor bleeding, spontaneous hematoma, eye bleeding, hemoptysis, gastrointestinal bleeding or ulcers,hematuria,reproductive system bleeding, traumatic hematoma/bleeding, and frequent epistaxis/gingival bleeding/subcutaneous or skin bleeding) were screened.
  9. Hemorrhoids or perianal diseases with regular/current hematochezia;
  10. surface antigen , virus antibody IgG test, antigen/antibody combination test, or Treponema pallidum antibody test is positive
  11. Use of any drug that affects drug metabolism enzymes or transporters (P-gp and BCRP) in the 30 days prior to screening, as detailed in Appendix 5;
  12. Have taken any prescription drugs, over-the-counter drugs, Chinese herbs or food supplements (vitamins, calcium supplements) in the 14 days prior to screening and before dosing;
  13. Participation in any other clinical trial (including drug and device clinical trials) within 3 months before screening;
  14. Habitual constipation or diarrhea;
  15. History of blood loss or donation (≥400mL) within 3 months before screening, received a transfusion or blood component within 1 month, or planned to donate blood within 3 months after the end of the trial;
  16. Daily smoking exceeding 5 cigarettes (≥ 5 cigarettes) within 3 months before Screening, or habitual use of nicotine-containing products and inability to withdraw during the trial period;
  17. Alcoholism or frequent alcohol use within 6 months before screening, i.e., weekly alcohol consumption > 14 units (1 unit = 360 mL of beer or 45 mL of ABV 40% spirit or 150 mL of wine),Or alcohol breath test >20mg/dL,or unable to abstain during the test
  18. Drug abuse, use of soft drug (e.g., marijuana) within 3 months before screening, or use of hard drug (e.g., cocaine, amphetamines, phencyclidine, etc.) within 1 year before screening; or positive urine drug test at screening;
  19. Habitual or excessive (more than 8 cups a day, 1 cup =250mL) consumption of grapefruit juice, tea, coffee and/or caffeinated beverages, and unable to abstain during the trial period;
  20. Those who have special requirements for diet and cannot abide by the uniform diet;
  21. History of long-term exposure to radioactive conditions, or significant radiation exposure (≥2 chest/abdominal CT, or ≥3 other kinds of X-ray examinations) within 1 year before administration, or participating in radiopharyngology labeling tests;
  22. History of needle fainting and blood fainting, difficulty in blood collection or inability to tolerate venous puncture blood collection;
  23. Vaccinated within 1 month before screening or planned to be vaccinated during the trial period;
  24. Subjects who with poor adherence or have any factors that make them not suitable for participating in this trial, as assessed by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    14C-labeled AL8326

    Single dose

    Drug: 14C-labeled AL8326

Interventions

  • Drug14C-labeled AL8326

    Oral, About 60mg (200μCi) of 14C-labeled AL8326

06

What researchers measure

Primary outcomes

  1. Material balance

    the cumulative excretion rate of total radioactive material in excreta (urine and feces);

    Time frame: All excreted urine and feces samples at specified time points during 0-480 hours after dosing will be collected.

  2. Metabolites

    The percentage of the original drug and each metabolite in urine and feces (% dose)

    Time frame: Conduct testing within 1 month after all subjects collect plasma, urine, and fecal samplesat all time points required by the protocol

  3. Metabolites

    The AUC percentage of the original drug and circulating metabolites in plasma (%AUC) were calculated;

    Time frame: Conduct testing within 1 month after all subjects collect plasma samplesat all time points required by the protocol

  4. Pharmacokinetic

    Pharmacokinetic parameters for total radioactivity in plasma, including peak concentration (Cmax), time to peak (Tmax), area under the drug-time curve (AUC0-t and AUC0-∞), elimination half-life (t1/2), apparent clearance (CL/F), apparent volume of distribution (Vd/F) and mean residence time (MRT). ) and mean residence time (MRT).

    Time frame: Conduct testing within 1 month after all subjects collect plasma samplesat all time points required by the protocol

  5. whole blood

    whole blood to plasma total radioactivity partition ratio

    Time frame: Conduct testing within 1 month after all subjects collect plasma samplesat all time points required by the protocol

Secondary outcomes

  1. Plasma pharmacokinetics

    PK parameters of AL8326 and its main metabolites in plasma, including peak concentration (Cmax), time to peak (Tmax), area under the drug-time curve (AUC0-t and AUC0-∞), elimination half-life (t1/2), apparent clearance (CL/F), apparent volume of distribution (Vd/F) and mean residence time (MRT). ) and mean residence time (MRT).

    Time frame: Conduct testing within 1 month after all subjects collect plasma, urine, and fecal samplesat all time points required by the protocol

  2. Safety

    Number of participants with adverse events/drug-related adverse events, with abnormal physical examination findings, abnormal vital signs, abnormal 12-lead electrocardiogram, and abnormal laboratory tests results

    Time frame: From signing the ICF until 22 days after the first dosing

07

Study locations

1 site
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in May 2025, 2 months.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's 2 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Aug 20, 2025
StartActual
Feb 21, 2025
Primary completionActual
May 17, 2025
CompletionActual
May 17, 2025
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07132957
Lead sponsor
Advenchen Laboratories Nanjing Ltd.
Responsible party
Sponsor
First posted
Aug 20, 2025
Start date
Feb 21, 2025
Primary completion
May 17, 2025
Completion
May 17, 2025
Last update
Aug 20, 2025

Study contacts

LiYan Miao
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion